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1Dermatological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
BACKGROUND: Metastatic melanoma is the most deadly form of skin cancer and with an overall 5-year survival rate ofo11%, there is
an acute need for novel therapeutic strategies. Activating mutations in the BRAF oncogene are present in 50–70% of cases and
contribute to tumourigenesis, thus, defining downstream targets of oncogenic BRAF may help define novel targets for therapeutic
intervention. The Ca2þ /calcineurin-regulated transcription factor, Nuclear factor of activated T-cells (NFAT), is important in the
pathogenesis of several human cancers, target genes of which are also known to contribute to melanoma progression. One such
NFAT target gene is COX-2, increased expression of which correlates with poor prognosis; however, upstream regulators of COX-2
in melanoma remain undefined. Therefore, the aim of this study was to evaluate NFAT expression and activity in metastatic
melanoma and establish whether or not oncogenic BRAF signalling modulates NFAT activity and determine if NFAT is a key
upstream regulator of COX-2 in melanoma.
METHODS: Nuclear factor of activated T-cells transcriptional activity and protein expression were determined in three human
metastatic melanoma cell lines with differing B-RAF mutational status. NFAT activation by oncogenic BRAFV600E was explored by
BRAFV600E overexpression and application of the specific MEK inhibitor PD98059. Regulation of COX-2 expression by NFAT was
investigated using NFAT-targeted siRNA, calcineurin inhibitors cyclosporin A and FK506, in addition to COX-2 luciferase reporter
vectors that selectively lacked NFAT binding sites.
RESULTS: NFAT transcriptional activity was increased in BRAF-mutated melanoma cells compared with wild-type cells. Furthermore, in
wild-type cells, overexpression of BRAFV600E increased NFAT activity, which was blocked by the MEK inhibitor PD98059. Using
calcineurin inhibitors and siRNA-mediated knockdown of NFAT2 and 4, we show NFAT is required for COX-2 promoter activation
and protein induction in metastatic melanoma cells.
CONCLUSION: NFAT2 and 4 are expressed in human metastatic melanoma cell lines and are activated by oncogenic BRAFV600E via
MEK/ERK signalling. NFAT is an important upstream regulator of COX-2 in metastatic melanoma. Furthermore, as the BRAF/MEK/
ERK pathway is hyperactive in other malignancies and MEK/ERK are also activated by oncogenic RAS in 30% of all human cancers, the
potential to exploit NFAT signalling for therapeutic benefit warrants further investigation.
British Journal of Cancer (2009) 101, 1448–1455. doi:10.1038/sj.bjc.6605277 www.bjcancer.com
Published online 1 September 2009
& 2009 Cancer Research UK
Keywords: B-RAF; NFAT; melanoma; COX-2


































































Malignant melanoma (MM) is the most lethal form of skin cancer
and represents an increasing world health problem currently
responsible for around 48 000 deaths worldwide each year (www.
WHO.int). MM is notoriously unresponsive to current chemo-
therapy and with an overall 5-year survival rate of o11%, there
is an acute need for novel therapeutic strategies (Dhomen and
Marais, 2007).
Perhaps the greatest recent advance in understanding risk
factors predisposing to melanoma has been the discovery of
activating mutations in the BRAF gene, occurring in 50–70% of all
melanomas (Davies et al, 2002; Dhomen and Marais, 2007). NRAS
mutations are also common in melanoma occurring in up to 30%
of cases, and as the occurrence of NRAS or BRAF mutation in
melanoma is mutually exclusive, up to 90% of melanomas harbour
a mutated, hyperactive Ras–RAF signalling pathway (Davies et al,
2002). Understanding downstream effectors of oncogenic BRAF
signalling may, therefore, facilitate the identification of novel
therapeutic targets. B-RAF is a serine–threonine kinase belonging
to the RAF-extracellular signal-regulated kinase (ERK) kinase
(MEK)/ERK pathway, which regulates diverse cellular processes
including proliferation, differentiation and apoptosis (Dhomen
and Marais, 2007). The BRAFV600E activating mutation accounts
for approximately 90% of BRAF mutations in melanoma and
BRAFV600E drives melanomagenesis in mice (Dhomen and Marais,
2007; Dankort et al, 2009). Inhibition of mutant BRAF signalling in
melanoma cell lines reduces proliferation, migration, increases
susceptibility to apoptosis induction and ablates tumour formation
in mice (Karasarides et al, 2004; Sharma et al, 2005, 2006).
Although BRAF is also mutated in up to 80% of benign
melanocytic naevi (Pollock et al, 2003), the proportion of naevi
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harbouring a BRAF mutation that progress to melanoma is small,
underscoring that further genetic events are required for the
development of melanoma. Furthermore, it has now been
established that after initial oncogenic activation and prolifera-
tion, naevi become senescent and events that overcome or evade
senescence are crucial for melanoma development in mice
(Michaloglou et al, 2005). Nevertheless, the mechanisms by which
BRAF signalling promotes melanoma development and/or pro-
gression to metastatic disease are not well defined and effective
melanoma therapy remains elusive.
Although pre-clinical studies indicate that blocking oncogenic
BRAF signalling provides a promising strategy for MM treatment,
current clinical trials are yet to demonstrate whether pharmaco-
logical targeting of the BRAF/MEK/ERK pathway represents an
effective treatment for melanoma as a monotherapy. Although the
efficacy of such agents may be improved by combination with
conventional chemotherapeutics (Haass et al, 2008), the functional
redundancy between pathways driving tumour progression and
acquired chemoresistance, nevertheless, leaves a demand for
alternative drug targets. For example, prolonged treatment of
BRAFV600E-expressing melanoma cells with the BRAF inhibitor
AZ628, leads to the development of clones that maintain high
levels of phosphorylated ERK, which continue to proliferate in the
presence of drug (Montagut et al, 2008). The identification of novel
targets for use in combination chemotherapy may therefore help
to combat acquired chemoresistance and oncogenic-signalling
redundancy.
Nuclear factor of activated T cells (NFAT) proteins were
originally defined as a family of Ca2þ /calcineurin-dependent
transcription factors required for T-cell activation (Hogan et al,
2003). Outwith the immune system, NFAT is functionally
important in the muscle, the bone, the skin (Flockhart et al,
2008) and the neural tissue, involved in diverse functions including
proliferation, angiogenesis and apoptosis (Hogan et al, 2003;
Zaichuk et al, 2004). Four Ca2þ /calcineurin-regulated NFAT
proteins (NFAT1–4) have been identified that reside hyper-
phosphorylated in the cytosol. Dephosphorylation by the
Ca2þ -dependent phosphatase calcineurin evokes NFAT nuclear
translocation and transcriptional activation where NFAT drives
gene transcription (Hogan et al, 2003).
Pertinent to tumour biology, deregulated or abnormal expres-
sion of NFAT has been reported in a number of haematological
malignancies and solid tumours (Medyouf and Ghysdael, 2008),
and we have recently shown that NFAT is preferentially activated
by carcinogenic UVB radiation in keratinocytes (Flockhart et al,
2008). Furthermore, accumulating evidence suggests that increased
NFAT transcriptional activity contributes to both the development
and progression of cancer (Buchholz and Ellenrieder, 2007), and
identifies NFAT signalling as a potential target for cancer therapy.
In the context of melanoma, increased expression of the NFAT
target gene cyclooxygenase-2 (COX-2), an inducible enzyme
involved in the conversion of arachidonic acid to prostaglandins,
correlates with poor prognosis (Kuzbicki et al, 2006; Chwirot
and Kuzbicki, 2007), suggesting that NFAT signalling may be
important in melanoma. However, upstream activators of COX-2
in melanoma and a role for oncogene-driven NFAT activation
remain undefined.
Outwith the cancer context, an important role for the Ras/RAF/
MEK/ERK signalling axis in regulating NFAT transcriptional
activity has been established in immune cells and in myocytes.
An effective adaptive immune response relies partly on the
production of IL-2 by T cells after T-cell receptor (TCR) activation,
which proceeds via MAPK/NFAT signalling. In T cells, dominant
negative BRAF or MEK inhibition completely abolished activated
TCR-driven ERK activation, IL-2 promoter activation and activa-
tion of NFAT1 and 2 indicating the importance of MAPK/NFAT
signalling in immune cell biology (Tsukamoto et al, 2004).
Similarly, stimulating cardiac myocytes with phenylephrine, a
ligand that contributes to cardiac hypertrophy, induced NFAT
activation that was blocked by MEK/ERK inhibition (Ichida and
Finkel, 2001). NFAT therefore serves as a putative downstream
target of activated MAPK signalling in non-cancerous cells,
however, a role for oncogene-driven MAPK/NFAT signalling has
not been described.
The aim of the present study was to test the hypothesis that
NFAT may be an important downstream target of oncogenic BRAF
in melanoma and that NFAT is involved in regulating COX-2
expression. We show that NFAT is activated by oncogenic
BRAFV600E in human metastatic melanoma cell lines via canonical
MEK/ERK signalling. In addition, we identify that COX-2
expression is regulated by NFAT in BRAF-mutated melanoma cell
lines, therefore highlighting that NFAT can be activated by
oncogene mutation and that NFAT regulates downstream factors,
which are important in melanoma biology.
MATERIALS AND METHODS
Cell culture and chemicals
The human metastatic melanoma cell lines A375, CHL-1 and
WM266-4 (American Type Culture Collection, Teddington, UK)
were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
(Lonza, Basel, Switzerland) supplemented with 10% foetal bovine
serum, penicillin and streptomycin in a humidified incubator at
371C/5% CO2. Primary human melanocytes were identified in
cultures of primary keratinocytes obtained from human foreskin
samples and isolated by selective trypsinisation, as previously
described (Lovat et al, 2008). Primary melanocytes were cultured
in medium-254 supplemented with melanocyte growth supple-
ments (Invitrogen, Paisley, UK) plus antibiotics. Chemicals
purchased were as follows; 12-O-tetradecanoylphorbol-13-acetate
(TPA), ionomycin, FK506 (Sigma, Poole, UK), Cyclosporin A
(Merk Chemicals Ltd, Nottingham, UK) and PD98059 (Promega,
Southampton, UK).
Luciferase assays
Nuclear factor of activated T-cells transcriptional activity was
measured using an NFAT-dependent luciferase reporter
(p(NFAT)9-luc) (Wilkins et al, 2004) (a gift from JD Molkentin,
Children’s Hospital Medical Center, Cincinnati, OH, USA). In all
luciferase experiments cells were co-transfected with a renilla
luciferase control vector (pRLTK, Promega) and reporter firefly
values were normalised to renilla values. Assays were carried out
using the dual luciferase assay system (Promega). Cells were
seeded in 24-well culture plates and transfected with 0.5 mg of
firefly reporter plus 0.0125 mg of renilla control using Lipofecta-
mine 2000 reagent and Opti-MEM medium (Invitrogen) according
to manufacturer’s instructions. For BRAF overexpression experi-
ments, cells were transfected with 0.5mg firefly reporter, 0.25mg
BRAF expression vector (pEFmBRAFWT or pEFmBRAFV600E
(Davies et al, 2002), kind gifts from R. Marais, Institute of Cancer
Research, London, UK) and 0.0125 mg renilla. COX-2 luciferase
reporters were transfected, as described above, and were gifts from
M.A. Iniguez, Centro de Biologia Molecular, Madrid, Spain
(In˜iguez et al, 2000).
siRNA-mediated gene silencing
Small interfering RNA (siRNA) targeting NFAT2 (cat. no.
SI03057684) and NFAT4 (cat. no. SI03114118) (Qiagen, Crawley,
UK) was transfected at a final concentration of 40 nM using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions. Cells were incubated for 48 h after transfection then
treated with TPA (50 nM) and ionomycin (1mM) for 4 h and cell
lysates were prepared for western blotting.
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mRNA extraction and real-time qPCR
Total mRNA was extracted using an RNeasy kit (Qiagen) and con
verted to cDNA using a high capacity cDNA reverse transcriptase
kit (Applied Biosystems, Warrington, UK) according to the manu
facturer’s instructions. Expression of NFAT mRNA was deter-
mined using a customised gene expression card (Applied Bio
systems) and real-time qPCR was carried out using the ABI Prism
7900HT sequence detection system.
Western blotting
Total protein was extracted from cell pellets, resolved by SDS–
PAGE (Web Scientific, Crewe, Cheshire, UK), and transferred to
PVDF membranes, blocked and probed as previously described
(Flockhart et al, 2008). In all, 30 mg of protein was loaded per lane.
Antibodies used were as follows: COX-2 (1 : 100), BRAF (1 : 1000),
NFAT3 (1 : 1000) and NFAT4 (1 : 500) (Santa Cruz Biotechnology,
Autogen Bioclear, Calne, UK), ERK and phospho-ERK (1 : 1000,
Cell Signalling Technology, New England Biolabs, Hitchin, UK),
and NFAT2 (1 : 1000, BD Biosciences, Oxford, UK). Equal protein
loading was confirmed by blotting for b-actin (1 : 40 000, Sigma) or
GAPDH (1 : 2000, Cell Signalling Technology). Antibody signal was
detected using HRP-conjugated secondary antibodies (1 : 2000,
Millipore Ltd, Watford, UK) and membranes were visualised
using ECL Plus reagent (Amersham Biosciences, Buckinghamshire,
UK) and a Fujifilm FLA-3000 fluorescent image analyzer.
Statistical analysis
Statistical analysis was performed using GraphPad Prism version
5. 00, GraphPad Software (San Diego, CA, USA).
RESULTS
NFAT activity and expression in metastatic melanoma cell
lines
Basal NFAT transcriptional activity was measured in three human
metastatic melanoma cell lines with different BRAF mutational
status. CHL-1 cells are BRAF wild-type, whereas A375 and
WM266-4 cells harbour BRAFV600E and BRAFV600D mutations
respectively (Dhomen and Marais, 2007). NFAT transcriptional
activity was approximately 10-fold higher in A375 cells
and approximately 70-fold higher in WM266-4 cells compared
with BRAF wild-type CHL-1 cells (Figure 1A), consistent
with increased B-RAF activity of BRAFV600D compared with
BRAFV600E (Wan et al, 2004). At the mRNA level, NFAT2 and
to a greater extent NFAT4 were expressed in all the three cell
lines and in primary melanocytes, whereas NFAT3 mRNA was
expressed exclusively in primary melanocytes, and NFAT1
expression was not detected in any cell type (Figure 1B). We
therefore examined the expression of NFAT2, 3 and 4 proteins
in primary melanocytes and in the metastatic cell lines. Three
previously described NFAT2 isoforms (Hogan et al, 2003) were
expressed in primary melanocytes but were absent in CHL-1 cells,
whereas their expression was higher in A375 cells and had further
increased in WM266-4 cells (Figure 1C). NFAT3 protein was
exclusively expressed in primary melanocytes (Figure 1C). NFAT4
protein was not detected in primary melanocytes and was
expressed at low levels in CHL-1 cells, whereas expression had
increased in A375 cells and elevated further in WM266-4 cells
(Figure 1C). These data suggest that NFAT2 and NFAT4 are the
active NFAT proteins that contribute to the NFAT activity shown
in Figure 1A.
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Figure 1 Nuclear factor of activated T-cells (NFAT) transcriptional activity, mRNA expression and protein expression in melanoma cell lines. (A) NFAT
transcriptional activity measured in three human metastatic melanoma cell lines. BRAF mutational status is indicated for reference. Values are means from
four independent experiments carried out in triplicate (± s.e.m.). (B) NFAT mRNA expression in primary melanocytes and in three metastatic melanoma
cell lines as determined by real-time qPCR. Values are mean 2DCt from RNA derived from two independent cultures (± s.d.). (C) Western blots indicate
the expression of three previously described NFAT2 isoforms, NFAT3 protein and NFAT4 protein. 11¼ primary melanocytes, CHL¼CHL-1 cells,
WM¼WM266-4 cells. Equal protein loading was confirmed by blotting for b-actin. Statistical analysis in (A) performed by one-way ANOVA, * Pp0.05,
** Pp0.01, *** Pp0.001.
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NFAT is activated by oncogenic BRAFV600E
As data in Figure 1 indicated NFAT transcriptional activity was
higher in BRAF-mutated melanoma cells; activation of NFAT by
mutant BRAF was further investigated. Inhibition of BRAF/MEK/
ERK signalling using the highly specific MEK inhibitor PD98059
resulted in a reduction in NFAT transcriptional activity among all
three melanoma cell lines (Figure 2A). PD98059 also reduced the
amount of phosphorylated-ERK1/2, thereby confirming inhibition
of MEK/ERK signalling and that MEK/ERK signals regulate
NFAT activity (Figure 2A). We next assessed the effect of
overexpression of BRAFWT or the most common BRAF mutation
in melanoma, BRAFV600E, on NFAT transcriptional activity in
CHL-1 cells. Overexpression of BRAFWT had no effect on NFAT
activity, whereas BRAFV600E induced a significant three-fold
increase that was blocked by PD98059 (Figure 2B). Western
blotting confirmed overexpression of BRAFWT and BRAFV600E,
BRAFV600E-induced ERK phosphorylation and inhibition of
BRAFV600E-induced ERK phosphorylation by PD98059
(Figure 2B). These data indicate that BRAFV600E increases NFAT
transcriptional activity via MEK/ERK-dependent signalling
(Figure 2C).
NFAT regulates COX-2 protein induction in metastatic
melanoma cell lines
The importance of NFAT signalling in regulating COX-2 promoter
activation and protein production was evaluated in BRAF-mutated
melanoma cells using COX-2 luciferase reporter vectors that
selectively lacked functional NFAT binding sites, calcineurin
inhibitors and siRNA-mediated knockdown of NFAT2 and 4.
Treating A375 and WM266-4 cells with the classical NFAT
activators TPA and ionomycin (TPA/iono) (Hogan et al, 2003)
increased both NFAT transcriptional activity (Figure 3A) and
COX-2 promoter activity (Figure 3B) that was blocked by the
calcineurin inhibitors CsA and FK506. This induction/inhibition
approach was then employed to establish effects of NFAT
inhibition on COX-2 protein induction. Treating A375 and
WM266-4 cells with TPA/iono induced a profound increase in
COX-2 protein expression that was markedly reduced by CsA and
FK506 (Figure 3C). In addition, as NFAT2 and 4 were shown to be
expressed in A375 and WM266-4 cells (Figure 1), we decided to
ablate NFAT2 and 4 protein using siRNA to show that specific
NFAT proteins regulate COX-2 protein induction. Indeed, knock-
down of NFAT2 or NFAT4 reduced COX-2 protein induction in
these cells (Figure 4).
Additional COX-2 luciferase reporter experiments indicated
functional NFAT binding sites in the COX-2 promoter were
required for maximal COX-2 induction (Figure 5). The human
COX-2 promoter contains two NFAT binding sites and COX-2
luciferase reporter vectors that selectively lacked either one or both
of these sites were used to further assess the importance of NFAT
as a regulator of the COX-2 promoter (schematic in Figure 5A).
Basal COX-2 promoter activity and activity induced by TPA/iono
was assessed. Treating A375 and WM266-4 cells with TPA/iono
increased the COX-2 promoter activity and this response was
reduced in vectors that contained mutated distal (dmut) or
proximal (pmut) sites compared with the vector containing both
functional NFAT binding sites (274) (Figure 5B, C). Basal promoter
activity was slightly reduced in vectors with either dmut or pmut
sites, whereas the vector with both NFAT sites mutated reported
minimal activity. The reporter vector with both NFAT sites
mutated (d/pmut) was not induced at all by TPA/iono in either cell
type (Figure 5B, C). Collectively, these data provide evidence that
NFAT regulates COX-2 promoter activity and induction of COX-2
protein in metastatic melanoma cells.
DISCUSSION
Previous studies have shown that NFAT signalling is important in
haematological malignancies and solid tumours (Buchholz and
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Figure 2 BRAFV600E activates nuclear factor of activated T-cells (NFAT) through a extracellular signal-regulated kinase kinase (MEK)-dependent pathway.
(A) NFAT transcriptional activity was measured 16 h after treatment with the MEK inhibitor PD98059 (10 mM). Values are means from three independent
experiments carried out in triplicate (±s.e.m.). Identically treated samples were prepared for western blotting and membranes were probed for
phosphorylated extracellular signal-regulated kinase (ERK) (pERK 1/2) and total ERK (ERK 1/2). (B) The effect of BRAFWT or BRAFV600E overexpression on
NFAT transcriptional activity in CHL-1 cells was measured by co-transfecting cells with an NFAT luciferase reporter±vectors expressing BRAFWT or
BRAFV600E. BRAFV600E-expressing cells were also treated with PD98059 where indicated. Untreated cells were transfected with NFAT reporter plus
transfection reagent only and NFAT luciferase activity was measured 48 h later. Values are normalised to the untreated control and are means from four
independent experiments carried out in triplicate (±s.e.m.). Identically treated samples were prepared for western blotting to confirm BRAFWT and
BRAFV600E overexpression and downstream ERK phosphorylation. Equal protein loading was confirmed by blotting for GAPDH. Statistical analysis
performed by t-test (A) or one-way ANOVA (B), ** Pp0.01, *** Pp0.001 vs vehicle control. (C) Schematic of BRAFV600E-induced NFAT activation.
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Ellenrieder, 2007; Medyouf and Ghysdael, 2008) and that NFAT is
activated by environmental carcinogens such as ultraviolet
radiation (Flockhart et al, 2008), but a role for oncogene
mutation-driven NFAT signalling has not been previously
described. Although a6b4 integrin signals stimulate NFAT activity
in breast cancer (Jauliac et al, 2002), we now identify that NFAT
is activated by oncogenic BRAF signalling, which is the most
frequently mutated gene in melanoma and a gene frequently
mutated in many other cancers. Activating BRAF mutations are
present in 29–69% of papillary thyroid carcinomas (Wojciechows-
ka and Lewinski, 2006), are also common in colorectal cancers
(Ogino et al, 2009) and present in 4% of small cell lung cancers
(Halilovic and Solit, 2008). Identifying that NFAT functions
downstream of mutant BRAF in melanoma, raises the possibility
that NFAT may be similarly activated in other BRAF-mutated
cancers.
Mechanistically, our data indicate that activation of NFAT
by oncogenic BRAFV600E involves canonical BRAF/MEK/ERK
signalling. Studies in myocytes and T and B lymphocytes indicate
that non-oncogenic Ras/RAF signalling increases NFAT activity via
ERK activation concurrent with results from this study (Ichida and
Finkel, 2001; Tsukamoto et al, 2004). Although MAPK signalling in
a non-oncogenic context has been shown to be an important
regulator of NFAT activity, the mechanism responsible for this is
not completely understood. It is interesting to note that elevated
MEK/ERK signalling stimulates AP-1 complex formation which is
a well established binding-partner of NFAT that supports NFAT-
mediated gene transcription (Macian et al, 2000, 2001). In
addition, MEK, ERK, calcineurin and NFAT4 are able to form a
large molecular weight protein complex in cardiac myocytes, and
although active MEK/ERK signalling did not affect NFAT at the
nuclear localisation level, MEK/ERK signalling did increase DNA
binding of NFAT4 (Sanna et al, 2005). In this context, increased
NFAT transcriptional activity required AP-1 complex formation
(Sanna et al, 2005). It is therefore possible that oncogenic Ras/RAF
signalling may increase DNA binding and transcriptional activity
of NFAT proteins via a MEK/ERK-dependent mechanism that may
also require AP-1 complex formation. Further studies to elucidate
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Figure 3 Nuclear factor of activated T-cells (NFAT) inhibition blocks cyclooxygenase-2 (COX-2) protein induction. Cells were transfected with either an
NFAT luciferase reporter (A) or COX-2 luciferase reporter (B) and pretreated for 2 h with vehicle (DMSO, Vh), CsA (1 mM) or FK506 (1mM) before TPA
(50 nM)/ionomycin (iono) (1mM) treatment. Luciferase activity was measured 4 h after TPA/iono treatment and results are shown for A375 and WM266-4
cells. (C) Western blot samples were treated exactly as in luciferase experiments and induction of COX-2 protein is shown for A375 and WM266-4 cells.
The three immunoreactive bands present are previously described, glycosylated variants of COX-2 protein. Equal protein loading was confirmed by blotting
for b-actin. In (A) and (B) values are means from three independent experiments carried out in triplicate (± s.e.m.). Statistical analysis performed by one-
way ANOVA, *** Pp0.001 vs cells treated with TPA/ionoþVh.
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the mechanism by which MEK/ERK signals increase NFAT
transcriptional activity are required particularly, since MEK/
ERK/NFAT signalling may be important in other cancers.
Our observation that NFAT activity was higher in V600D-
mutated WM266-4 cells compared with V600E-mutated A375 cells,
which correlated with the amount of BRAF kinase activity evoked
by each mutant is particularly noteworthy. The V600E mutation
confers an increase in BRAF kinase activity of approximately 480
times compared with wild-type BRAF, whereas the V600D
mutation increases this by approximately 700 times (Wan et al,
2004). The level of inhibition of NFAT activity by PD98059 also
correlated with the ability of PD98059 to reduce levels of phospho-
ERK consistent with the notion that NFAT activity is regulated
in-part by MEK/ERK-dependent signalling in melanoma cells.
Increased amounts of PD98059 were not used in an effort to
further reduce phospho-ERK levels in WM266-4 cells, as increased
concentrations of PD98059 can exert non-specific effects. Although
MEK inhibition resulted in the downregulation of NFAT activity in
BRAF mutant melanoma cells, this effect was also evident in BRAF
wild-type CHL-1 cells, although the absolute levels of NFAT
activation were substantially lower. This is not surprising as MEK/
ERK signalling is still functional, albeit at lower levels in CHL-1
cells. Indeed, the low threshold level of pERK in these cells may
promote their sensitisation to MEK inhibition.
The involvement of MEK/ERK activation raises the possibility
that other upstream signals activating MEK/ERK may increase
NFAT activity. This is highly significant as oncogenic RAS (active
in approximately 30% of all human cancers) signals partly via
MEK/ERK (Schubbert et al, 2007), thus further investigation of
NFAT signalling in the context of oncogenic Ras/RAF is merited.
The identification of COX-2 as a direct transcriptional target of
NFAT in melanoma suggests targeting NFAT/COX-2 signalling
may offer a novel therapeutic strategy. COX-2 contributes to
tumourigenesis through stimulation of cell proliferation, angio-
genesis and tumour metastasis (Buchholz and Ellenrieder, 2007).
Recent clinical trials of the specific COX-2 inhibitor celecoxib
suggest that COX-2 inhibition may increase the clinical efficacy of
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Figure 4 Small interfering RNA (siRNA)-mediated knockdown of
nuclear factor of activated T-cells (NFAT) 2 or NFAT4 reduces
cyclooxygenase-2 (COX-2) protein induction. WM266-4 and A375 cells
were transfected with siRNA targeting either NFAT2 (A) or NFAT4 (B).
48 h post-transfection, cells were treated with TPA (50 nM) and ionomycin
(1mM) (T/I). UT¼ untreated control sample. At 4 h after treatment, cell
lysates were prepared for western blotting. Membranes were probed with
antibodies to detect NFAT2 (A), NFAT4 (B) and COX-2. Equal protein
loading was confirmed by blotting for b-actin.
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Figure 5 Nuclear factor of activated T-cells (NFAT) regulates
cyclooxygenase-2 (COX-2) promoter activity in melanoma cell lines. (A)
Schematic of the human COX-2 promoter and the COX-2 luciferase
reporter vectors used. Cells were transfected with the panel of reporter
vectors and treated 24 h later with TPA (50 nM)/ionomycin (iono) (1mM)
for 4 h. Reporter activity is shown for A375 cells (B) and WM266-4 cells
(C). Values are means from three independent experiments performed in
triplicate (± s.e.m.). Statistical analysis performed by one-way ANOVA,
**Pp0.01, *** Pp0.001 vs control vector containing all functional NFAT
binding sites ($).
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temozolomide for melanoma treatment (Gogas et al, 2006).
Furthermore, as COX-2 is more highly expressed in cutaneous
melanoma and metastatic melanoma compared with benign naevi
(Chwirot and Kuzbicki, 2007), defining upstream regulators could be
valuable for drug development. Pertinent to cancer pathogenesis and
metastasis, c-myc and VEGF are additional transcriptional targets of
NFAT (Buchholz and Ellenrieder, 2007), further emphasising the
relevance of NFAT signalling for melanoma therapy.
Although the classical calcineurin/NFAT inhibitors CsA and
FK506 revolutionised transplant biology by inducing immunosup-
pression via NFAT inactivation in T cells, their potential
application in cancer therapy remains untested. The value of
CsA and FK506 per se may be limited as long term, systemic
application in transplant patients causes renal toxicity and
increases cancer risk because of reduced immunosurveillance
(Botti et al, 1998; Sheil, 1998). Novel analogues of CsA and FK506
named ISATX247 and L732531 respectively, exhibit significantly
less toxicity while retaining efficacy, and may have a place in future
cancer therapy directed at NFAT inhibition (Dumont, 2000;
Aspeslet et al, 2001; Stalder et al, 2003). Alternatively, novel small
peptides that block calcineurin/NFAT interaction without inhibit-
ing calcineurin phosphatase activity have exhibited efficacy for
inhibiting NFAT in vivo in the absence of significant toxicity
(Yu et al, 2007) and may prove to be valuable as therapeutic NFAT
antagonists.
In summary, NFAT is expressed and is transcriptionally active
in human metastatic melanoma cell lines and is activated by
oncogenic BRAFV600E via canonical MEK/ERK signalling. Although
NFAT is overexpressed in other cancers, activation has never
previously been linked to the mutation of a specific oncogene. Data
indicating that COX-2 expression in melanoma is regulated by
NFAT further suggest that NFAT merits additional investigation as
a transcription factor important in melanoma biology. Further-
more, given that Ras/RAF signalling is highly activated in many
other human cancers, the potential to exploit NFAT signalling for
therapeutic benefit clearly warrants further investigation.
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